Search Results

Agricola

Record details

Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.

• Authors : Natale P; Sydney School of Public Health, The University of Sydney, Sydney, Australia.; Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Subjects: Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects ; Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/Renal Insufficiency, Chronic*/complications

• Source: The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2024 May 21; Vol. 5. Cochrane AN: CD015588. Date of Electronic Publication: 2024 May 21.Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X

Record details

Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.

• Authors : Yu MK; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Vart P

Subjects: Glucosides*/Glucosides*/Glucosides*/therapeutic use ; Glucosides*/Glucosides*/Glucosides*/adverse effects ; Benzhydryl Compounds*/Benzhydryl Compounds*/Benzhydryl Compounds*/therapeutic use

• Source: Journal of general internal medicine [J Gen Intern Med] 2024 May; Vol. 39 (6), pp. 921-930. Date of Electronic Publication: 2023 Dec 14.Publisher: Springer Country of Publication: United States NLM ID: 8605834 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study.

• Authors : Manski-Nankervis JA; Department of General Practice, University of Melbourne, Carlton, Australia. .; Thuraisingam S

Subjects: General Practice*; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Dipeptidyl-Peptidase IV Inhibitors/Dipeptidyl-Peptidase IV Inhibitors/Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage

• Source: BMC family practice [BMC Fam Pract] 2019 Feb 18; Vol. 20 (1), pp. 29. Date of Electronic Publication: 2019 Feb 18.Publisher: BioMed Central Country of Publication: England NLM ID: 100967792 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2296

Record details

The association between sodium glucose cotransporter-2 inhibitors vs dipeptidyl peptidase-4 inhibitors and renal outcomes in people discharged from hospital with type 2 diabetes: A population-based cohort study.

• Authors : Ziser KED; Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Victoria, Australia.; Wood S

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/epidemiology ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use

• Source: Journal of diabetes [J Diabetes] 2024 Apr; Vol. 16 (4), pp. e13507.Publisher: Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101504326 Publication Model: Print Cited

Record details

Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.

• Authors : Heerspink HJ; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands; The George Institute for Global Health, Sydney, New South Wales, Australia.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use

• Source: American heart journal [Am Heart J] 2024 Apr; Vol. 270, pp. 125-135. Date of Electronic Publication: 2024 Feb 15.Publisher: Mosby Country of Publication: United States NLM ID: 0370465 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6744

Record details

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.

• Authors : Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.; The George Institute for Global Health, Sydney, New South Wales, Australia.

Subjects: Benzhydryl Compounds* ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Glucosides*

• Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association [Nephrol Dial Transplant] 2024 Feb 28; Vol. Publisher: Oxford University Press Country of Publication: England NLM ID: 8706402 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.

• Authors : Neuen BL; The George Institute for Global Health, University of New South Wales, Sydney, Australia (B.L.N., H.J.L.H., R.A.F., C.A., B.N., V.P.).; Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia (B.L.N.).

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/Sodium-Glucose Transporter 2 Inhibitors*/adverse effects

• Source: Circulation [Circulation] 2024 Feb 06; Vol. 149 (6), pp. 450-462. Date of Electronic Publication: 2023 Nov 12.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0147763 Publication Model: Print-Electronic Cited Medium:

Record details

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.

• Authors : Sharma A; Centre for Outcomes Research and Evaluation Research Institute of the McGill University Health Centre Montreal QC Canada.; Division of Cardiology McGill University Health Centre, McGill University Montreal QC Canada.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy

• Source: Journal of the American Heart Association [J Am Heart Assoc] 2024 Feb 06; Vol. 13 (3), pp. e031586. Date of Electronic Publication: 2024 Jan 19.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification.

• Authors : Pollock C; Royal North Shore Hospital, Kolling Institute, University of Sydney, St Leonards, New South Wales, Australia.; Sanchez JJG

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Metformin*/Metformin*/Metformin*/adverse effects

• Source: Diabetic medicine : a journal of the British Diabetic Association [Diabet Med] 2024 Feb; Vol. 41 (2), pp. e15200. Date of Electronic Publication: 2023 Aug 26.Publisher: Blackwell Science Country of Publication: England NLM ID: 8500858 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details